Azhar Khan

572 total citations
26 papers, 421 citations indexed

About

Azhar Khan is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Reproductive Medicine. According to data from OpenAlex, Azhar Khan has authored 26 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 6 papers in Endocrinology, Diabetes and Metabolism and 6 papers in Reproductive Medicine. Recurrent topics in Azhar Khan's work include Ovarian function and disorders (5 papers), Growth Hormone and Insulin-like Growth Factors (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Azhar Khan is often cited by papers focused on Ovarian function and disorders (5 papers), Growth Hormone and Insulin-like Growth Factors (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). Azhar Khan collaborates with scholars based in United Kingdom, Pakistan and United States. Azhar Khan's co-authors include Malcolm Rowland, Vanya Beltrami, Hervé Porchet, Jean-Yves le Cotonnec, Leon Aarons, Stephen Toon, Paul Rolan, Denys deCatanzaro, Svend E. Møller and Elliott A. Beaton and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Gut.

In The Last Decade

Azhar Khan

24 papers receiving 385 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Azhar Khan United Kingdom 11 204 165 66 64 60 26 421
Uche Anadu Ndefo United States 10 119 0.6× 88 0.5× 91 1.4× 88 1.4× 87 1.4× 21 447
Muqing Gu China 14 143 0.7× 112 0.7× 36 0.5× 164 2.6× 93 1.6× 35 458
L Marianowski Poland 10 134 0.7× 42 0.3× 21 0.3× 60 0.9× 51 0.8× 59 377
Jiao Xiao China 8 120 0.6× 69 0.4× 42 0.6× 168 2.6× 29 0.5× 15 358
Irène Feroce Italy 12 102 0.5× 82 0.5× 119 1.8× 152 2.4× 24 0.4× 33 521
P I Adnitt United Kingdom 9 146 0.7× 43 0.3× 63 1.0× 86 1.3× 42 0.7× 16 400
Kathryn A. Maurer United States 12 169 0.8× 50 0.3× 119 1.8× 120 1.9× 12 0.2× 24 548
U. Karck Germany 11 43 0.2× 60 0.4× 24 0.4× 82 1.3× 25 0.4× 20 368
Jafaru Abu United Kingdom 11 179 0.9× 72 0.4× 49 0.7× 119 1.9× 26 0.4× 22 460
Mei‐Tzu C. Tang United States 10 65 0.3× 66 0.4× 231 3.5× 62 1.0× 60 1.0× 26 379

Countries citing papers authored by Azhar Khan

Since Specialization
Citations

This map shows the geographic impact of Azhar Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Azhar Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Azhar Khan more than expected).

Fields of papers citing papers by Azhar Khan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Azhar Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Azhar Khan. The network helps show where Azhar Khan may publish in the future.

Co-authorship network of co-authors of Azhar Khan

This figure shows the co-authorship network connecting the top 25 collaborators of Azhar Khan. A scholar is included among the top collaborators of Azhar Khan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Azhar Khan. Azhar Khan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Khan, Azhar, et al.. (2024). The Impact of Artificial Intelligence (AI) on Job Displacement and the Future Work. 2(2). 2296–2306. 1 indexed citations
3.
Ni, Lan, Azhar Khan, Amanda Long, et al.. (2023). Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm. Clinical Pharmacology & Therapeutics. 114(1). 77–87. 3 indexed citations
4.
Tabernero, Josep, Atsushi Ohtsu, Kei Muro, et al.. (2017). Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics. 16(10). 2215–2222. 34 indexed citations
5.
Khan, Azhar, et al.. (2015). Adverse effects of maternal age, weight and smoking during pregnancy in Pleven, Bulgaria. SHILAP Revista de lepidopterología. 3 indexed citations
6.
Tabernero, Josep, Atsushi Ohtsu, Kei Muro, et al.. (2015). Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer.. Journal of Clinical Oncology. 33(3_suppl). 121–121. 19 indexed citations
7.
Baetz, Tara, Elizabeth A. Eisenhauer, Lillian L. Siu, et al.. (2006). A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Investigational New Drugs. 25(3). 217–225. 25 indexed citations
8.
Beaton, Elliott A., Azhar Khan, & Denys deCatanzaro. (2006). Urinary Sex Steroids during Sexual Development in Female Mice and in Proximate Novel Males. Hormone and Metabolic Research. 38(8). 501–506. 14 indexed citations
9.
Møller, Svend E., Frank Larsen, Azhar Khan, & Paul Rolan. (2001). Lack of Effect of Citalopram on the Steady-State Pharmacokinetics of Carbamazepine in Healthy Male Subjects. Journal of Clinical Psychopharmacology. 21(5). 493–499. 19 indexed citations
10.
Aarons, Leon, Malcolm Rowland, Azhar Khan, et al.. (1998). Plasma and tonsillar tissue pharmacokinetics of teicoplanin following intramuscular administration to children. European Journal of Pharmaceutical Sciences. 6(4). 265–270. 6 indexed citations
11.
Cotonnec, Jean-Yves le, et al.. (1998). Clinical Pharmacology of Recombinant Human Follicle-Stimulating Hormone (FSH). I. Comparative Pharmacokinetics with Urinary Human FSH. Fertility and Sterility. 69(3). 16S–24S. 52 indexed citations
12.
Davis, John D., et al.. (1996). Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers. British Journal of Clinical Pharmacology. 42(2). 246–248. 3 indexed citations
13.
Beltrami, Vanya, et al.. (1995). Comprehensive Pharmacokinetics of Urinary Human Follicle Stimulating Hormone in Healthy Female Volunteers. Pharmaceutical Research. 12(6). 844–850. 5 indexed citations
14.
Cotonnec, Jean-Yves le, et al.. (1994). Clinical pharmacology of recombinant human follicle-stimulating hormone. II. Single doses and steady state pharmacokinetics. Fertility and Sterility. 61(4). 679–686. 51 indexed citations
15.
Cotonnec, Jean-Yves le, et al.. (1994). Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertility and Sterility. 61(4). 669–678. 59 indexed citations
16.
Toon, Stephen, et al.. (1994). Absence of effect of ranitidine on blood alcohol concentrations when taken morning, midday, or evening with or without food. Clinical Pharmacology & Therapeutics. 55(4). 385–391. 15 indexed citations
17.
Toon, Stephen, et al.. (1992). Small bowel/nutrition. Gut. 33(1 Suppl). S10–S13. 1 indexed citations
18.
Khan, Azhar & Leon Aarons. (1989). Design and analysis of protein binding experiments. Journal of Theoretical Biology. 140(2). 145–166. 5 indexed citations
19.
Khan, Azhar & Leon Aarons. (1989). A note on the use of salicylate saliva concentration in clinical pharmacokinetic studies. Journal of Pharmacy and Pharmacology. 41(10). 710–711. 5 indexed citations
20.
Aarons, Leon, et al.. (1985). The binding of flurbiprofen to plasma proteins. Journal of Pharmacy and Pharmacology. 37(9). 644–646. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Uche Anadu Ndefo Breakdown of academic impact, for papers by Muqing Gu Breakdown of academic impact, for papers by L Marianowski Breakdown of academic impact, for papers by Jiao Xiao Breakdown of academic impact, for papers by Irène Feroce Breakdown of academic impact, for papers by P I Adnitt Breakdown of academic impact, for papers by Kathryn A. Maurer Breakdown of academic impact, for papers by U. Karck Breakdown of academic impact, for papers by Jafaru Abu Breakdown of academic impact, for papers by Mei‐Tzu C. Tang
Rankless by CCL
2026